Pfizer – Allergan

A new Pharma Mega-Deal making Botox and Viagra join forces. On November 23, 2015, Pfizer announced its $160bn tie-up with Allergan to form the world’s biggest pharmaceutical company by sales. Industry Overview Even though recent M&A activity has started to slow down in the healthcare sector, the announced merger shows that the M&A frenzy is … Continue reading Pfizer – Allergan

A NEW OUTBURST OF THE HEALTHCARE M&A FIRE – TEVA TO ACQUIRE ALLERGAN

Teva Pharmaceutical Industries will pay $40.5bn in cash and stock for Allergan’s generic drug business, sustaining Teva’s position as the world’s number one producer of generics. Industry Overview Teva Pharmaceutical Industries Ltd. is an international pharmaceutical company with its headquarters in Israel. Its main business is producing generic drugs, but it also has business in … Continue reading A NEW OUTBURST OF THE HEALTHCARE M&A FIRE – TEVA TO ACQUIRE ALLERGAN

THE END OF A TRILOGY – VALEANT ON SALIX CASE.

The increased M&A activity within the Healthcare sector has not slowed down in 2015, after we saw a record volume of transactions in the previous year. After securing financing, Canada-based Valeant has won a tender offer for Salix Pharmaceuticals, in a $14.5bn transaction. The market trend of increased deal activity for tax-inverted players still continues. … Continue reading THE END OF A TRILOGY – VALEANT ON SALIX CASE.

ACTAVIS ACQUIRES BOTOX-MAKER ALLERGAN FOR $66BN

The acquisition of Allergan Inc. (NYSE:AGN) by Actavis Plc. (NYSE:ACT) will lead to the creation of one of the biggest pharmaceutical companies in the world. The $66bn deal is expected to be closed by the second quarter of 2015. The acquisition by Actavis brings an end to the months-long pursuit of Allergan by the Canadian … Continue reading ACTAVIS ACQUIRES BOTOX-MAKER ALLERGAN FOR $66BN